KPMG Australia Cuts 5% of Workforce Amid Scandal 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Trump Buys SpaceX Shares After Record IPO 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
SK Hynix Shares Fall as Workers Reject Wage Deal 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Add as a preferred source on Google
SAN DIEGO, May 02, 2018 -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Chief Scientific Officer, will present at the Deutsche Bank 43rd Annual Health Care Conference in Boston on Wednesday, May 9, 2018 at 10:40 a.m. ET.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-specific antigens. The Company’s immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
[email protected]
